Dr. Nagourney's Blog

Email-box.png

Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

The Cost of Care for Stage 4 Colon Cancer: How Much is Too Much?
By Robert A. Nagourney, MD
Among the most important topics of discussion at cancer meetings today is the cost of cancer care. Terms like “financial toxicity” are used to describe the growing out-of-pocket and institutional expenses associated with the use of advanced...
Bevacizumab In Colon Cancer – “A Shot Across The Bowel”
By Robert A. Nagourney, MD
An E-Publication article in the February Journal of Clinical Oncology analyzes the cost efficacy of Bevacizumab for colon...
A Tale of Two Trials - AML & Stage 3 Non Small Cell Lung Cancer
By Robert A. Nagourney, MD
As I read through the November 10 issue of the Journal of Clinical Oncology there were two very different but highly...
Breast Cancer and Avastin, the Ongoing Saga
By Robert A. Nagourney, MD
As many are now aware, in November of 2011, the United States FDA withdrew approval for bevacizumab (Avastin) for the treatment...
English Patients Denied Access to Ipilimumab
By Robert A. Nagourney, MD
Among the more interesting discoveries in recent years have been two breakthroughs in the management of malignant melanoma. One...
The Avastin Saga Continues
By Robert A. Nagourney, MD
We previously wrote about bevacizumab (Avastin) and its approval for breast cancer. The early clinical trials revealed evidence...
Are New Cancer Drugs Always Better? - Stage 4 Kidney Cancer Success
By Robert A. Nagourney, MD
Few cancers instill a greater sense of fear in the medical oncologist that metastatic renal cell carcinoma, the most common...

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.